<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01897402</url>
  </required_header>
  <id_info>
    <org_study_id>JN-NM-002</org_study_id>
    <nct_id>NCT01897402</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Group A, C, Y &amp; W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine</brief_title>
  <official_title>A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y &amp; W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT™) Compared With a Licensed Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JN-International Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JN-International Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the production of antibodies to a new conjugate
      vaccine, NmVac4-A/C/Y/W-135-DT, as a measure of vaccine effectiveness, compared to the
      production of antibodies to a similar, licensed meningococcal (Groups A, C, Y, W-135)
      polysaccharide diphtheria toxoid (DT) conjugate vaccine. The investigators will also evaluate
      the safety of NmVac4-A/C/Y/W-135-DT™ conjugate vaccine compared to the licensed vaccine. The
      hypothesis is that the test vaccine is comparable to the licensed active control vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meningococcal disease is a potentially life-threatening bacterial infection. The disease most
      commonly is expressed as either meningococcal meningitis, an inflammation of the membranes
      surrounding the brain and spinal cord, or meningococcemia, the presence of bacteria in the
      blood. The most common symptoms include high fever, headache, neck stiffness, confusion,
      nausea, vomiting, lethargy, and rash. If not treated the disease can progress rapidly and can
      lead to shock and death, often within hours of the onset of symptoms. The disease is fatal at
      a rate of 10%. Of patients who recover, 10% have permanent hearing loss or other serious
      sequelae.

      Neisseria meningitidis capsular polysaccharides are poor immunogens. However, conjugation of
      bacterial polysaccharides to immunogenic carrier proteins generally results in conjugates
      that induce strong anti-polysaccharide T-helper cell dependent immune responses, creating a
      longer-lasting immune response and thus protection against meningococcal infection.

      The sponsor's small size Phase 1 clinical trial comprised 60 subjects. Therefore, additional
      data is needed to confirm the previous data with a statistically powered Phase 2 clinical
      trial. The present study aims to evaluate subject responses to single doses, administered in
      adult subjects, to determine further safety and immunogenicity of the vaccine. This study
      compares safety and antibody production induced by one intramuscular injection of either
      NmVac4-A/C/Y/W-135-DT or a licensed meningococcal (Groups A, C, Y, W-135) polysaccharide
      diphtheria toxoid conjugate vaccine. The primary immunogenicity endpoint will be
      seroresponse, based on antibody titer ≥1:8 for subjects with titer &lt;1:8 at baseline or a
      4-fold rise in antibody levels, 4 weeks after a single injection . The number and proportion
      of subjects achieving seroresponse will be tabulated by serogroup for each vaccine group. A
      non-inferiority test will be used to determine if the immune response elicited by NmVac4
      A/C/Y/W-135-DT™ is not less than a specified difference in percent seroconversion from the
      licensed control vaccine. Participants will attend a screening visit up to 6 weeks prior to
      vaccination (day 0), then will attend study visits for 4 weeks. There will be a study phone
      call at days 2-3, then a post-study call to subjects to assess safety at 26 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroresponse (Percent Seroconversion).</measure>
    <time_frame>Week 4 after injection</time_frame>
    <description>Rise in antibody titers in serum at 4 weeks after vaccination, compared to baseline titer for meningococcal serogroups A, C, Y, and W-135. Serum Bactericidal Assay with human complement: Antibody titer ≥1:8 for subjects with titer &lt;1:8 at baseline or a 4-fold rise in antibody levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited Adverse Events From Diary Cards</measure>
    <time_frame>Day 0 to Day 7 after vaccination</time_frame>
    <description>Local and systemic rates from Diary Cards filled by the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non Solicited Adverse Events</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Non solicited local and systemic adverse Event (AE) rates throughout the course of the study, based on laboratory test results, vital signs, examination and questioning the subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">525</enrollment>
  <condition>Meningococcal Meningitis</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Test Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Licensed Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Test Vaccine</intervention_name>
    <description>NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.</description>
    <arm_group_label>Test Vaccine</arm_group_label>
    <other_name>meningococcal meningitis conjugate vaccine, quadrivalent</other_name>
    <other_name>NmVac4-A/C/Y/W-135-DT™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US Licensed Vaccine</intervention_name>
    <description>Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.</description>
    <arm_group_label>US Licensed Vaccine</arm_group_label>
    <other_name>meningococcal meningitis conjugate vaccine, quadrivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (IC):

          -  Participant is willing and able to give informed consent and comply with all aspects
             of the evaluation after the nature of the study is explained.

          -  Male or female, aged 18 to 55 years old

          -  In general good health with no significant chronic or acute conditions that would
             interfere with immune response or expected Adverse Event (AE) evaluation in the
             opinion of the investigator as determined by Medical history and/or History-directed
             physical examination

          -  Abstinence or use of effective contraception by the participants or their partners
             during the trial and continuing for four weeks after vaccination will be required for
             males or female participants of child bearing potential.

          -  Able (in the opinion of the investigator) to comply with all study requirements.

        Exclusion Criteria (EC):

          -  Unwilling or unable to understand study requirements and give written informed consent
             for the study.

          -  Prisoners.

          -  History of Guillain-Barré syndrome (GBS).

          -  Pregnancy (confirmed by positive pregnancy test) or lactation.

          -  Previous diagnosis of laboratory confirmed meningococcal disease.

          -  Previous meningococcal meningitis vaccination in the last five years

          -  Laboratory abnormalities that are considered Grade 2 or higher (based on AE, ranges as
             described in the protocol appendix) that in the opinion of the Investigator would
             raise safety concerns for participation in the study or interfere with evaluation of
             study objectives, or abnormalities &gt;2 times the Upper Limit of Normal range (ULN).

          -  Known or suspected autoimmune or connective tissue disorders, including rheumatoid
             arthritis and congenital or acquired immunodeficiency. Does not include mild to
             moderate seasonal/perennial allergies treated with over the counter antihistamines.

          -  Use of systemic immunosuppressive drugs or therapy within 6 months prior to study
             enrollment, not including topical or inhaled steroids/cytotoxic agents. Includes
             anti-cancer chemotherapy, radiation, and long term systemic corticosteroid therapy.
             History of anaphylactic shock, severe asthma, urticaria, or other allergic or
             hypersensitivity reactions following vaccination or known hypersensitivity to any
             vaccine component.

          -  Received blood, blood products, plasma derivatives or any parenteral immunoglobulin
             preparation in the past 3 months.

          -  Use of systemic antibiotics within 72 hours prior to study enrollment.

          -  History of cirrhosis or hepatitis.

          -  Known bleeding disorder or condition associated with a prolonged bleeding time.

          -  Positive results of testing for hepatitis B surface antigen (HepBsAg), Hepatitis C or
             HIV-1 or HIV-2 antibodies. Known or suspected HIV or Hepatitis B or C infection.

          -  Positive results of drug screen that cannot be explained by use of approved
             prescription medication (amphetamine, tetrahydrocannabinol (THC), cocaine). Current
             (past 30 days) heavy smokers (greater than or equal 1 pack per
             day).tetrahydrocannabinol

          -  Received another investigational product within the last 30 days. Investigational
             product may be a drug, vaccine, medical device or medical procedure.

          -  History of significant head trauma, alcohol or substance abuse or other medical
             illnesses that could cause a neurological deficit (e.g., cerebro-vascular disease).

          -  Medication or alcohol use that, in the opinion of the Investigator, may influence or
             bias the clinical outcome of the trial.

          -  History of any serious chronic medical or psychiatric illnesses or condition which, in
             the opinion of the investigator, might interfere with the evaluation of the study
             objectives.

          -  History of chronic or severe headaches, myalgia, arthralgia, malaise, fatigue or other
             systemic disorder commonly observed as AEs for licensed meningococcal vaccines.

          -  Currently experiencing a cold, flu or other acute illness (subject may be deferred
             until after recovery).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Yataco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRC Clinics,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey E Atkinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chesapeake Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myron I Murdock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid Atlantic Urology Associates LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mid Atlantic Urology Associates LLC</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRC Clinics</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>March 26, 2015</results_first_submitted>
  <results_first_submitted_qc>April 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2015</results_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central Nervous System Infections</keyword>
  <keyword>Meningitis</keyword>
  <keyword>toxoid</keyword>
  <keyword>Meningococcal vaccine</keyword>
  <keyword>conjugate vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited and were enrolled at three sites in Maryland between October 21, 2013 and May 22, 2014. The sites screened 1086 subjects with 559 screen failures. The majority, 390 subjects (69.8 %), failed due to inclusion or exclusion criteria (IC/EC). The most common failure criterion was Laboratory abnormalities (150 subjects, 26.8 %).</recruitment_details>
      <pre_assignment_details>Other common reasons for screen failure were inability to re-schedule within enrollment window after trial start was delayed (101 subjects, 18.1 % of screen failures) and lost to follow up 65 subjects (11.6%). These two reasons account for 166 (29.7%) subjects who met IC/EC, but did not enter the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Test Vaccine</title>
          <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine</description>
        </group>
        <group group_id="P2">
          <title>US Licensed Vaccine</title>
          <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Population contains all randomized subjects. Two randomized subjects could not be vaccinated. Three subjects, one female and 3 males received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (secondary outcomes).</population>
      <group_list>
        <group group_id="B1">
          <title>Test Vaccine</title>
          <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine</description>
        </group>
        <group group_id="B2">
          <title>US Licensed Vaccine</title>
          <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
            <count group_id="B2" value="261"/>
            <count group_id="B3" value="527"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="11.1"/>
                    <measurement group_id="B2" value="36.0" spread="10.88"/>
                    <measurement group_id="B3" value="36.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/ Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/ African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroresponse (Percent Seroconversion).</title>
        <description>Rise in antibody titers in serum at 4 weeks after vaccination, compared to baseline titer for meningococcal serogroups A, C, Y, and W-135. Serum Bactericidal Assay with human complement: Antibody titer ≥1:8 for subjects with titer &lt;1:8 at baseline or a 4-fold rise in antibody levels.</description>
        <time_frame>Week 4 after injection</time_frame>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Vaccine</title>
            <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
Test Vaccine: NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.</description>
          </group>
          <group group_id="O2">
            <title>US Licensed Vaccine</title>
            <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
US Licensed Vaccine: Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroresponse (Percent Seroconversion).</title>
          <description>Rise in antibody titers in serum at 4 weeks after vaccination, compared to baseline titer for meningococcal serogroups A, C, Y, and W-135. Serum Bactericidal Assay with human complement: Antibody titer ≥1:8 for subjects with titer &lt;1:8 at baseline or a 4-fold rise in antibody levels.</description>
          <population>Per Protocol Population</population>
          <units>percentage of per protocol participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="64.3" upper_limit="76.6"/>
                    <measurement group_id="O2" value="70.1" lower_limit="63.6" upper_limit="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="59.9" upper_limit="72.7"/>
                    <measurement group_id="O2" value="72.5" lower_limit="66.1" upper_limit="78.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" lower_limit="56.3" upper_limit="69.4"/>
                    <measurement group_id="O2" value="64.1" lower_limit="57.5" upper_limit="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" lower_limit="59.6" upper_limit="72.4"/>
                    <measurement group_id="O2" value="65.9" lower_limit="59.3" upper_limit="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that the test vaccine is comparable to the licensed active control vaccine. Differences between treatment groups were described using exact two-sided 95% confidence intervals on differences in % seroconversion between the two treatment groups (test vaccine minus reference vaccine) for each serogroup. If the lower bound of the difference is ≥ -15%, then the test vaccine meets the preliminary criterion for non-inferiority.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assumptions for the sample size calculations were: 1) Seroconversion for the control vaccine (Menactra) is 40-80% and 2) the true treatments are theoretically equal and 3) the power of detecting non-inferiority is 90%.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
            <estimate_desc>Serogroup A</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that the test vaccine is comparable to the licensed active control vaccine. Differences between treatment groups were described using exact two-sided 95% confidence intervals on differences in % seroconversion between the two treatment groups (test vaccine minus reference vaccine) for each serogroup. If the lower bound of the difference is ≥ -15%, then the test vaccine meets the preliminary criterion for non-inferiority.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assumptions for the sample size calculations were: 1) Seroconversion for the control vaccine (Menactra) is 40-80% and 2) the true treatments are theoretically equal and 3) the power of detecting non-inferiority is 90%.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-6.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
            <estimate_desc>Serogroup C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that the test vaccine is comparable to the licensed active control vaccine. Differences between treatment groups were described using exact two-sided 95% confidence intervals on differences in % seroconversion between the two treatment groups (test vaccine minus reference vaccine) for each serogroup. If the lower bound of the difference is ≥ -15%, then the test vaccine meets the preliminary criterion for non-inferiority.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assumptions for the sample size calculations were: 1) Seroconversion for the control vaccine (Menactra) is 40-80% and 2) the true treatments are theoretically equal and 3) the power of detecting non-inferiority is 90%.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
            <estimate_desc>Serogroup Y</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that the test vaccine is comparable to the licensed active control vaccine. Differences between treatment groups were described using exact two-sided 95% confidence intervals on differences in % seroconversion between the two treatment groups (test vaccine minus reference vaccine) for each serogroup. If the lower bound of the difference is ≥ -15%, then the test vaccine meets the preliminary criterion for non-inferiority.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assumptions for the sample size calculations were: 1) Seroconversion for the control vaccine (Menactra) is 40-80% and 2) the true treatments are theoretically equal and 3) the power of detecting non-inferiority is 90%.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
            <estimate_desc>Serogroup W-135</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited Adverse Events From Diary Cards</title>
        <description>Local and systemic rates from Diary Cards filled by the participants.</description>
        <time_frame>Day 0 to Day 7 after vaccination</time_frame>
        <population>Safety Population: All vaccinated participants, grouped by actual vaccine received.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Vaccine - Male</title>
            <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>Test Vaccine - Female</title>
            <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine</description>
          </group>
          <group group_id="O3">
            <title>US Licensed Vaccine - Male</title>
            <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</description>
          </group>
          <group group_id="O4">
            <title>US Licensed Vaccine - Female</title>
            <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Adverse Events From Diary Cards</title>
          <description>Local and systemic rates from Diary Cards filled by the participants.</description>
          <population>Safety Population: All vaccinated participants, grouped by actual vaccine received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="65.8"/>
                    <measurement group_id="O3" value="40.8"/>
                    <measurement group_id="O4" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="34.7"/>
                    <measurement group_id="O4" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non Solicited Adverse Events</title>
        <description>Non solicited local and systemic adverse Event (AE) rates throughout the course of the study, based on laboratory test results, vital signs, examination and questioning the subjects.</description>
        <time_frame>up to 6 months</time_frame>
        <population>Safety Population: All vaccinated participants, grouped by actual vaccine received.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Vaccine</title>
            <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>US Licensed Vaccine</title>
            <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Non Solicited Adverse Events</title>
          <description>Non solicited local and systemic adverse Event (AE) rates throughout the course of the study, based on laboratory test results, vital signs, examination and questioning the subjects.</description>
          <population>Safety Population: All vaccinated participants, grouped by actual vaccine received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least 1 treatment related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs: vaccination day and 7 days following vaccination (participant diary cards, Outcome 2). AEs were also collected at each visit (4 weeks) and by phone calls 2-3 day following vaccination and at 6 months following vaccination (Outcome 3).</time_frame>
      <desc>Methods: standard questionnaire, investigator assessment, laboratory testing, scheduled telephone calls.
Solicited AEs (secondary outcome 2) and non solicited AEs (secondary outcome 3) are included in the other adverse event totals. All AEs meeting the 4% threshold except increased blood pressure were solicited AEs from diary cards.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Vaccine</title>
          <description>NmVac4-A/C/Y/W-135-DT™ conjugate vaccine</description>
        </group>
        <group group_id="E2">
          <title>US Licensed Vaccine</title>
          <description>Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <description>Not associated with the vaccine. All 3 Serious Adverse Events affected the same subject.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate Decreased</sub_title>
                <description>Not associated with the vaccine. All 3 Serious Adverse Events affected the same subject.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Not associated with the vaccine. All 3 Serious Adverse Events affected the same subject.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tenderness around injection site</sub_title>
                <description>Local from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Pain around injection site</sub_title>
                <description>Local from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Hardness around injection site</sub_title>
                <description>Local from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Swelling around injection site</sub_title>
                <description>Local from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Systolic Increased</sub_title>
                <description>Systemic</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Systemic from Dairy Cards</description>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All abstracts, presentations or manuscripts, and any data analyses conducted independently by the Investigator must be submitted in advance to the sponsor for review and approval. The sponsor will not unreasonably withhold publication of study findings. The objective of this policy is to ensure consistency between data filed with a regulatory authority and those appearing in the publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Three subjects, 1 female and 2 males, received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (outcomes 2 and 3).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Regulatory Affairs Director</name_or_title>
      <organization>JN-International Medical Corporation</organization>
      <phone>4028843477</phone>
      <email>dr_orten@jn-vaccines.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

